Page last updated: 2024-10-21

tramiprosate and Amyotrophic Lateral Sclerosis

tramiprosate has been researched along with Amyotrophic Lateral Sclerosis in 1 studies

tramiprosate: GABA receptor agonist and a glycosaminoglycan mimetic; has nootropic acitivity; structure; a sulfonate analog of GABA
3-aminopropanesulfonic acid : An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.

Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Renner, M1
Melki, R1

Reviews

1 review available for tramiprosate and Amyotrophic Lateral Sclerosis

ArticleYear
Protein aggregation and prionopathies.
    Pathologie-biologie, 2014, Volume: 62, Issue:3

    Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autophagy; Biopolymers; Clinical T

2014